Patent SG-11201910096R-A (SG)
Title: Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
Inventor: WALKER LAURA M
IPC: C07K16/28
Filed: 2018-05-08
Abstract: Days 28 Days 42 Days 7 Days I Immunization Strategy Primary Immunization 1 st Boost 2 nd Boost 3 rd Boost Sac Primary Immunization: 1.0x10 6 Purified Human T Cells with Sigma Adjuvant in Each of 10 mice 1 8 t Boost: 1.0x10 6 Purified Human T Cells with Sigma Adjuvant in Each of 10 Mice 2nd Boost: 1.5x10 6 Purified T Cells with Sigma Adjuvant; 5 of the Mice with Human T Cells, the other 5 Mice with Cynomoigus T-Cells 3rd Boost: 50 ug Denatured Cyno CD3 Protein Mixed with 7 ug N-terminal Peptide-BSA (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT omit o His u Elio° im mom oimIE (10) International Publication Number WO 2018/208864 Al Figure 1 C (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/28 A61K 39/395 (2006.01) C07K 16/30 C07K 16/18 (2006.01) C07K 16/32 (21) International Application Number: PCT/US2018/031705 (22) International Filing Date: 08 May 2018 (08.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/503,315 08 May 2017 (08.05.2017) US (71) Applicant: ADIMAB, LLC [US/US]; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (72) Inventors: WALKER, Laura M.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). PEJCHAL, Robert; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). KRAULAND, Er- ic; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hamp- shire 03766 (US). VASQUEZ, Maximiliano; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). LEUNG, Monica Wai Ling; c/o Celgene Corpora- tion, 86 Morris Avenue, Summit, New Jersey 07901 (US). (74) Agent: SAHR, Robert N. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (2006.01) (2006.01) (2006.01) (54) Title: ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENER- ATION AND USE 00 00 O (57) : Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desk- able T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their 0 identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, gen- \" crating and characterizing CD3 binding domains and antibodies comprising them are also provided. [Continued on next page] WO 2018/208864 Al MIDEDIMOMMIDIRE101001010MHOHNHIMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))